Skip to main content

Patricia Pozo Rosich

I am a doctor of medicine, specialist in neurology. I am head of the Neurology Service of Vall d'Hebron. I lead the Research Laboratory in Cephalea and Neurological Pain of the VHIR (Vall d’Hebron Research Institute) belonging to the Autonomous University of Barcelona (UAB).

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital

Patricia Pozo Rosich

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital

I am a doctor of medicine, specialist in neurology. I am head of the Neurology Service of Vall d'Hebron. I lead the Research Laboratory in Cephalea and Neurological Pain of the VHIR (Vall d’Hebron Research Institute) belonging to the Autonomous University of Barcelona (UAB).

I am a member of the Executive Committee of the International Headache Society and the European Headache Federation and of the Committee for Clinical Trials of the International Headache Society. In addition, I am a member of the American Headache Society.

I specialized in the field of headache in the United States and London, in the laboratories of Professor Silberstein (Thomas Jefferson University) and Professor Goadsby (University of California at San Francisco and University College London – Queen Square), with the help of the “la Caixa” scholarships, AHS, EFNS, Rio Hortega, GECSEN.

My interest in the field of research focuses on better understanding the pathophysiology of migraine from a multidisciplinary approach using genetics, neuroimaging and electrophysiology. I have developed the Migraine Adaptive Brain research program that focuses on the neurosensory brain. I am a member of the International Consortium of Migration Genetics.

To carry out research projects I have received grants from the “la Caixa” Banking Foundation, the FIS (Health Research Fund) of the Carlos III Institute, the La MaratóTV3 Foundation, Migraine Research Foundation, MICINN (Ministry of Science and Innovation) and the Mutual Medical.

I am editor of the journals Frontiers in Neurology, Journal of Headache and Pain and director of the Cephalia Area of the Neurology Journal. I have published original articles in impact factor journals, review articles, book chapters, edited books and magazines and I am the author of books.

I also work in education. I am a clinical associate professor at the Autonomous University of Barcelona.

Projects

BIOMIGA: un abordaje multidisciplinar para la identificacion de biomarcadores en migraña: estudio prueba de concepto basado en la estratificación de respondedores a anticuerpos monoclonales contra el CGRP

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Marta Torres Ferrús, Victor José Gallardo Lopez
Funding agency: Instituto de Salud Carlos III
Funding: 99999.97
Reference: AC19/00124
Duration: 01/01/2020 - 30/06/2024

Sol·licitud Juan de la Cierva-Formación

IP: Patricia Pozo Rosich
Collaborators: -
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 50000
Reference: FJC2018-036804-I
Duration: 01/04/2020 - 31/03/2022

Títol: Cluster Emergent del Cervell Humà (CECH)

IP: Patricia Pozo Rosich
Collaborators: -
Funding agency: Generalitat de Catalunya
Funding: 131250
Reference: 001-P-001682
Duration: 01/01/2019 - 31/12/2022

Estudio de la adaptación del cerebro a los estímulos: Migraine Adaptive Brain Program

IP: Patricia Pozo Rosich
Collaborators: -
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 82476.49
Reference: SLT006/17/00265
Duration: 21/05/2018 - 31/12/2019

Related news

Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.

Related professionals

Andrea Casal Pardo

Andrea Casal Pardo

Predoctoral researcher
Kidney Physiopathology
Read more
Sergi Martí Beltran

Sergi Martí Beltran

Pneumology
Read more
Belén Moro

Belén Moro

P. Management and Admin. Technical specialist
Pre-Award Project Unit
Competitive Research Directorate
Read more
Miriam  Moratal  Cloquell

Miriam Moratal Cloquell

General Surgery
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.